- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07291414
En självövervakningsplattform för att följa läkemedelssäkerhet och oro hos cancerpatienter
Patientengagemang i användningen av tekniken för självspårning av läkemedelssäkerhetshändelser
This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.
Studieöversikt
Status
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- University of Michigan Comprehensive Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Participants are adult patients (aged 18 years or older)
- Diagnosed with lung, colorectal, breast, or prostate cancer
- Are currently receiving active cancer treatments
- Are self-managing one or more prescribed cancer medications
- Participants must have access to technology devices (smartphone, tablet, computer) to track their experiences or concerns about medication safety events, or their family members can help them access technology devices to track the events or concerns
- Speaks and reads English or has a support person (family member or friend) who can assist
Exclusion Criteria:
- Can't access technology or do not use technology
- Do not have access to the internet
- Do not speak or read English
- Not permitted to participate by their health care providers
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Health services research (self-monitoring platform)
Patients use the self-monitoring platform to track medication-related safety events and issues at home for 6 months. Patients may receive relevant educational materials and resources via the platform or by email and/or receive follow-up contact from a nurse practitioner as needed over the 6 months. Patients are encouraged to continue using the platform for an additional 6 months after the study period, as desired. |
Ancillary studies Ancillary studies Ancillary studies Receive educational materials and resources
Andra namn:
Receive follow-up contact
Andra namn:
Use self-monitoring platform |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Self-reported system usability
Tidsram: Up to 6 months
|
Self-reported system usability will be assessed using the 10-item System Usability Scale. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables. |
Up to 6 months
|
|
Perceived usefulness
Tidsram: Up to 6 months
|
Qualitative data, including brief interview data will be analyzed and summarized through content analysis. |
Up to 6 months
|
|
Ease of use
Tidsram: Up to 6 months
|
Qualitative data, including brief interview data will be analyzed and summarized through content analysis. |
Up to 6 months
|
|
Attitudes toward use
Tidsram: Up to 6 months
|
Qualitative data, including brief interview data will be analyzed and summarized through content analysis. |
Up to 6 months
|
|
Intention to use and continuous use of the system over time
Tidsram: Up to 12 months
|
Qualitative data, including brief interview data will be analyzed and summarized through content analysis. |
Up to 12 months
|
|
Self-reported patient engagement
Tidsram: Up to 6 months
|
Self-reported patient engagement will be measured by the 9-item Twente Engagement with Ehealth Technologies Scale (TWEETS), including three dimensions, behavioral engagement, cognitive engagement, and affective engagement. Will use the overall TWEETS score to evaluate patient engagement in this study, rather than analyzing each dimension separately. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables. Will use repeated measures analysis of variance to assess the changes in mean scores of patient engagement. Univariate associations between baseline personal and clinical factors and patient engagement at each time point will be assessed using correlation analyses (Pearson or Spearman), Chi-square tests, or non-parametric Mann-Whitney U tests, depending on the variable types. Multiple linear regressions will be conducted to assess associations between patient engagement and outcomes. |
Up to 6 months
|
|
System usage over time
Tidsram: Up to 12 months
|
Will be objectively recorded by the system logs and analyzed using Google Analytics (dashboard only), including parameters like the number of logins, number of tab pages clicked, number of events or concerns self-tracked, and more. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables. |
Up to 12 months
|
|
Patient activation levels
Tidsram: Up to 6 months
|
Patient activation levels will be measured by the Short Form of Patient Activation Measure. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables. |
Up to 6 months
|
|
Medication self-management ability
Tidsram: Up to 6 months
|
Medication self-management ability will be measured by the Measure of Medication Self-Management. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables. |
Up to 6 months
|
|
Symptom distress
Tidsram: Up to 6 months
|
Symptom distress will be measured by the 19-item MD Anderson Symptom Inventory. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables. |
Up to 6 months
|
|
Health related quality of life
Tidsram: Up to 6 months
|
Health-related quality of life will be measured by the 27-item Functional Assessment of Cancer Therapy - General. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables. |
Up to 6 months
|
|
Number of emergency room visits
Tidsram: Up to 12 months
|
Will be measured by both self-report and chart review. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables. |
Up to 12 months
|
|
Number of hospitalizations
Tidsram: Up to 12 months
|
Will be measured by both self-report and chart review. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables. |
Up to 12 months
|
|
User experiences with the system
Tidsram: Up to 6 months
|
Participants' user experiences with the system, such as perceived facilitators or barrios to system use, along with their suggestions for system improvement, will be collected through a brief individual interview. Qualitative data, including brief interview data will be analyzed and summarized through content analysis. |
Up to 6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Self-tracked, structured medication safety events or concerns
Tidsram: Up to 12 months
|
To understand the nature and causes of events and concerns, self-tracked, structured medication safety events or concerns tracking data from the system, such as the number and types of events or concerns self-tracked, will be summarized using descriptive statistics. The free-text tracking data from the system will be analyzed and summarized through content analysis or natural language processing techniques, depending on data volume. |
Up to 12 months
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Yun Jiang, University of Michigan Rogel Cancer Center
- Huvudutredare: Yang Gong, UTHealth Houston McWilliam School of Biomedical Informatics
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Genitala neoplasmer, manliga
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Genitala sjukdomar, manliga
- Prostatasjukdomar
- Manliga urogenitala sjukdomar
- Tarmsjukdomar
- Luftvägssjukdomar
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Lungsjukdomar
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Kolonsjukdomar
- Hudsjukdomar
- Bröstsjukdomar
- Hud- och bindvävssjukdomar
- Prostatiska neoplasmer
- Lungneoplasmer
- Kolorektala neoplasmer
- Bröstneoplasmer
- Sjukvårdskvalitet, tillgång och utvärdering
- Undersökningstekniker
- Epidemiologiska metoder
- Datainsamling
- Hälsovårdsutvärderingsmekanismer
- Hälsovårdskvalitet
- Folkhälsa
- Miljö och folkhälsa
- Vårdtjänster
- Sjukvårdsanläggningar och tjänster
- Barnhälsotjänster
- Gemenskapens hälsovård
- Förebyggande hälsovårdstjänster
- Socioekonomiska faktorer
- Befolkningsegenskaper
- Immunologiska tekniker
- Genetiska tekniker
- Epidemiologiska studier
- Epidemiologiska studieegenskaper
- Kromatinimmunutfällning
- Nukleotidsekvensering
- Sekvensanalys
- Sekvensanalys, DNA
- Immunutfällning
- Kohortstudier
- Metoder
- Intervjuer som ämne
- Tidig intervention, pedagogisk
- Utbildningsstatus
- Kromatinimmunutfällningssekvensering
- Uppföljningsstudier
Andra studie-ID-nummer
- UMCC 2025.050
- NCI-2025-08754 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- HUM00272763 (Annan identifierare: University of Michigan)
- R01HS027846 (U.S.A. AHRQ-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .